1.Anti-Allodynic Effects of Levodopa in Neuropathic Rats.
Hue Jung PARK ; Hwan Seok JOO ; Young Hoon KIM ; Ou Kyoung KWON ; Jaemin LEE ; Eun Sung KIM ; Dong Eon MOON
Yonsei Medical Journal 2013;54(2):330-335
PURPOSE: Levodopa is the most effective anti-Parkinsonian agent. It has also been known to exhibit analgesic properties in laboratory and clinical settings. However, studies evaluating its effects on neuropathic pain are limited. The aim of the present study was to examine the anti-allodynic effects of levodopa in neuropathic rats. MATERIALS AND METHODS: Sprague-Dawley male rats underwent the surgical procedure for L5 and L6 spinal nerves ligation. Sixty neuropathic rats were randomly divided into 6 groups for the oral administration of distilled water and levodopa at 10, 30, 50, 70, and 100 mg/kg, respectively. We co-administered carbidopa with levodopa to prevent peripheral synthesis of dopamine from levodopa, and observed tactile, cold, and heat allodynia pre-administration, and at 15, 30, 60, 90, 120, 150, 180, and 240 min after drug administration. We also measured locomotor function of neuropathic rats using rotarod test to examine whether levodopa caused side effects or not. RESULTS: Distilled water group didn't show any difference in all allodynia. For the levodopa groups (10-100 mg/kg), tactile and heat withdrawal thresholds were increased, and cold withdrawal frequency was decreased dose-dependently (p<0.01). In addition, levodopa induced biphasic analgesia. Different dosage of levodopa did not impact on the rotarod time (p>0.05). CONCLUSION: Levodopa reversed tactile, cold and heat allodynia in neuropathic rat without any side effects.
Animals
;
Carbidopa/administration & dosage/adverse effects/therapeutic use
;
Dopamine Agents/administration & dosage/adverse effects/*therapeutic use
;
Hyperalgesia/*drug therapy
;
Levodopa/administration & dosage/adverse effects/*therapeutic use
;
Male
;
Neuralgia/*drug therapy
;
Rats
;
Rats, Sprague-Dawley
;
Rotarod Performance Test
2.Profound hypotension immediately following insertion of methyl methacrylate during bipolar endoprosthesis in a patient with long-term levodopa-treated paralysis agitans.
Yong Chul KIM ; Moon Seong CHO ; Sung Soon KIM ; Soo Yeong KIM ; Yoon Geun LEE ; Tae Hwan KIM ; Sung Ryang JUNG
Journal of Korean Medical Science 1995;10(1):31-35
Insertion of methyl methacrylate polymer into newly reamed bony cavities has sometimes resulted in profound hypotension, cardiac arrest, or sudden death which are more common in patients with hemodynamic instability or hypovolemia. In paralysis agitans(Parkinson's disease), dramatic worsening of the disease often occurs when another illness or trauma accompanies it. And it is possible that chronic medication with levodopa can cause the loss of ability to support blood pressure. So, it involves some risk to use methyl methacrylate in chronic levodopa-treated paralysis agitans. We present a case of paralysis agitans who demonstrated profound hypotension immediately following insertion of methyl methacrylate polymer in spite of normovolemia and proper anesthetic management.
Aged
;
Case Report
;
Hip Prosthesis/adverse effects
;
Human
;
Hypotension/*etiology
;
Levodopa/therapeutic use
;
Male
;
Methylmethacrylate
;
Methylmethacrylates/*adverse effects
;
Parkinson Disease/*drug therapy
3.Evaluation on the efficacy and safety of Chinese herbal medication Xifeng Dingchan Pill in treating Parkinson's disease: study protocol of a multicenter, open-label, randomized active-controlled trial.
Jie ZHANG ; E-mail: MAYUNZHI6688@SOHU.COM. ; Yun-zhi MA ; Xiao-ming SHEN
Journal of Integrative Medicine 2013;11(4):285-290
BACKGROUNDParkinson's disease (PD) is a complicated disease, commonly diagnosed among the elderly, which leads to degeneration of the central nervous system. It presently lacks an effective therapy for its complex pathogenesis. Adverse effects from Western drug-based medical intervention prevent long-term adherence to these therapies in many patients. Traditional Chinese medicine (TCM) has long been used to improve the treatment of PD by alleviating the toxic and adverse effects of Western drug-based intervention. Therefore, the aim of this study is to evaluate the efficacy and safety of Xifeng Dingchan Pill (XFDCP), a compound traditional Chinese herbal medicine, taken in conjunction with Western medicine in the treatment of PD patients at different stages in the progression of the disease.
METHODS AND DESIGNThis is a multicenter, randomized controlled trial. In total, 320 patients with early- (n = 160) and middle-stage PD (n = 160) will be enrolled and divided evenly into control and trial groups. Of the 160 patients with early-stage PD, the trial group (n = 80) will be given XFDCP, and the control group (n = 80) will be given Madopar. Of the 160 patients with middle-stage PD, the trial group (n = 80) will be given XFDCP combined with Madopar and Piribedil, and the control group (n = 80) will be given Madopar and Piribedil. The Unified Parkinson's Disease Rating Scale scores, TCM symptoms scores, quality of life, change of Madopar's dosage and the toxic and adverse effects of Madopar will be observed during a 3-month treatment period and through a further 6-month follow-up period.
DISCUSSIONIt is hypothesized that XFDCP, combined with Madopar and Piribedil, will have beneficial effects on patients with PD. The results of this study will provide evidence for developing a comprehensive therapy regimen, which can delay the progress of the disease and improve the quality of life for PD patients in different stages.
TRIAL REGISTRATIONThis trial has been registered in the Chinese Clinical Trial Registry with the identifer ChiCTR-TRC-12002150.
Benserazide ; therapeutic use ; Data Interpretation, Statistical ; Drug Combinations ; Drugs, Chinese Herbal ; adverse effects ; therapeutic use ; Humans ; Levodopa ; therapeutic use ; Medicine, Chinese Traditional ; Parkinson Disease ; drug therapy ; psychology ; Phytotherapy ; Piribedil ; therapeutic use ; Quality of Life
4.Effect of TCM treatment according to syndrome differentiation in enhancing curative effect and reducing side-effect of madopa.
Chinese Journal of Integrated Traditional and Western Medicine 2007;27(9):796-799
OBJECTIVETo observe the effect of TCM treatment according to syndrome differentiation in en-hancing curative effect and reducing side-effect of madopa in patients with Parkinson' s disease (PD).
METHODSThe trial was conducted in 101 PD patients with a prospective stratified randomized and controlled method. They were assigned to group 1 in which the patients of rigidity were treated with Pabing Recipe 1 (PR1) plus Madopa tablets, group 2 with those of tremor given Pabing Recipe 3 (PR3) plus Madopa tablets, and group 3 given a fixed Chinese recipe plus Madopa tablets as the control. The treatment course for all the groups was 3 months. Clinical efficacy was evaluated with unified Parkinson's disease rating scale (UPDRS) and the adverse reactions observed before and after treatment.
RESULTSAfter treatment, the 4 partial scores and the total score of UPDRS decreased significantly in group 2 (P<0.01), and the former of them and the total score declined in group 1 and 3 (P<0.01), the improvement was better in group 1 and 2 than that in group 3 (P<0.01); the improvement rate in group 1 to 3 was 95.5%, 100.0% and 83.7%, respectively, which was significantly higher in group 1 and 2 than that in group 3 (P<0.05).
CONCLUSIONTCM treatment according to syndrome differentiation could improve the clinical symptoms and reduce complications in PD patients, which could enhance curative effect and reduce side-effect of madopa.
Aged ; Aged, 80 and over ; Benserazide ; adverse effects ; therapeutic use ; Diagnosis, Differential ; Dopamine Agents ; adverse effects ; therapeutic use ; Drug Combinations ; Drug Synergism ; Drug Therapy, Combination ; Drug-Related Side Effects and Adverse Reactions ; etiology ; prevention & control ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Levodopa ; adverse effects ; therapeutic use ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Parkinson Disease ; diagnosis ; drug therapy ; Phytotherapy ; Prospective Studies ; Syndrome ; Treatment Outcome
5.Electrode Position and the Clinical Outcome after Bilateral Subthalamic Nucleus Stimulation.
Sun Ha PAEK ; Jee Young LEE ; Han Joon KIM ; Daehee KANG ; Yong Hoon LIM ; Mi Ryoung KIM ; Cheolyoung KIM ; Beom Seok JEON ; Dong Gyu KIM
Journal of Korean Medical Science 2011;26(10):1344-1355
We compared the surgical outcome with electrode positions after bilateral subthalamic nucleus (STN) stimulation surgery for Parkinson's disease. Fifty-seven patients treated with bilateral STN stimulations were included in this study. Electrode positions were determined in the fused images of preoperative MRI and postoperative CT taken at six months after surgery. The patients were divided into three groups: group I, both electrodes in the STN; group II, only one electrode in the STN; group III, neither electrode in the STN. Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr stage, and activities of daily living scores significantly improved at 6 and 12 months after STN stimulation in both group I and II. The off-time UPDRS III speech subscore significantly improved (1.6 +/- 0.7 at baseline vs 1.3 +/- 0.8 at 6 and 12 months, P < 0.01) with least L-dopa equivalent daily dose (LEDD) (844.6 +/- 364.1 mg/day at baseline; 279.4 +/- 274.6 mg/day at 6 months; and 276.0 +/- 301.6 mg/day at 12 months, P < 0.001) at 6 and 12 months after STN deep brain stimulation (DBS) in the group I. Our findings suggest that the better symptom relief including speech with a reduced LEDD is expected in the patients whose electrodes are accurately positioned in both STN.
Adult
;
Aged
;
Antiparkinson Agents/adverse effects/*therapeutic use
;
Combined Modality Therapy
;
*Deep Brain Stimulation/adverse effects/instrumentation/methods
;
*Electrodes, Implanted
;
Female
;
Humans
;
Levodopa/adverse effects/therapeutic use
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Parkinson Disease/drug therapy/*therapy
;
Severity of Illness Index
;
Subthalamic Nucleus/*physiology
;
Treatment Outcome